Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

Clinical trial NCT05030077 · UNKNOWN

Trial details

NCT number: NCT05030077
Sponsor: Tianjin Medical University Second Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Urothelial Carcinoma Anlotinib Urogenital Neoplasms Cisplatin Carboplatin Gemcitabine Antineoplastic Agents

Start date: 2021-10-01
Primary completion: 2023-09-01
Enrollment: 53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.